• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Codiak BioSciences Inc.

    5/2/23 1:35:25 PM ET
    $CDAK
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CDAK alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-39615
    Issuer: Codiak BioSciences, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 35 CambridgePark Drive, Suite 500
    Cambridge MASSACHUSETTS 02140
    Telephone number: 617-949-4100
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-05-02 By Aravind Menon Hearings Advisor
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CDAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDAK

    DatePrice TargetRatingAnalyst
    2/22/2022$34.00 → $24.00Outperform
    Wedbush
    2/11/2022$19.00Buy
    Goldman Sachs
    More analyst ratings

    $CDAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush reiterated coverage on Codiak BioSciences with a new price target

      Wedbush reiterated coverage of Codiak BioSciences with a rating of Outperform and set a new price target of $24.00 from $34.00 previously

      2/22/22 8:48:06 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Goldman Sachs initiated coverage on Codiak BioSciences with a new price target

      Goldman Sachs initiated coverage of Codiak BioSciences with a rating of Buy and set a new price target of $19.00

      2/11/22 6:11:40 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process

      CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the Company has voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets which is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties. The Company expects

      3/27/23 7:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference

      CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference. Codiak's Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:00 am ET and the Company will also be hosting one-on-one meetings at the conference. A live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. A

      11/28/22 1:00:00 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

      – exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 – – Systemically administered exoASO-C/EBPβ demonstrated extra-hepatic delivery and potent systemic anti-tumor activity across multiple myeloid-derived suppressor cell (MDSC) rich tumor models – – A Phase 1 clinical trial of exoASO-STAT6 in patients with advanced hepatocellular carcinoma (HCC), is ongoing; initial data expected in the first half of 2023 – CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a

      11/10/22 9:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Howze Yalonda

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 6:01:07 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Sathyanarayanan Sriram

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 5:19:21 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Konstantinov Konstantin

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 5:13:35 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Codiak BioSciences Inc.

      25-NSE - Codiak BioSciences, Inc. (0001659352) (Subject)

      5/2/23 1:35:25 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form NT 10-K filed by Codiak BioSciences Inc.

      NT 10-K - Codiak BioSciences, Inc. (0001659352) (Filer)

      3/28/23 7:34:56 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Codiak BioSciences Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Codiak BioSciences, Inc. (0001659352) (Filer)

      3/27/23 9:59:55 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care